- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2127399
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 31,409
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
- Conditions
- Sleep Disordered Breathing
- Interventions
- Standard of Care, DreamMapper Application, DreamMapper Application with Therapist Assist
- Other · Device
- Lead sponsor
- Philips Respironics
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Atlanta, Georgia • Indianapolis, Indiana + 2 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Diseases
- Interventions
- RSV Vaccine, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 5,815 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
- Conditions
- DSD, Hypospadias
- Interventions
- Narrative Medicine Journaling Intervention
- Behavioral
- Lead sponsor
- Sarah Schlegel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Physical Inactivty, Wellbeing, Mindfulness
- Interventions
- Mindful Movement, Keys to Health & Wellbeing
- Behavioral · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Burnsville, Minnesota • Edina, Minnesota • Minneapolis, Minnesota + 1 more
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- MK-3120
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more
- Conditions
- Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
- Interventions
- Selinexor
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
- Interventions
- Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
- Device
- Lead sponsor
- Jaguar LAA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
- Conditions
- Glaucoma
- Interventions
- Bare Contact Lens, Experimental Smart Contact Lens, Commercially available smart contact lens
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- Amputation, Prosthesis Use
- Interventions
- Training with PRC, Training with DC, PRC Device use in community and home, DC Device use in community and home
- Device
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Austin, Texas • Richmond, Virginia
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Eltrombopag, Cyclosporine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Preclinical Alzheimer's Disease
- Interventions
- Obicetrapib 10 mg, Matching placebo tablets
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Obesity, Childhood
- Interventions
- Arm 1, Arm 2, Arm 3, Brighter Bites app
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Arthritis, Psoriatic
- Interventions
- JNJ-88545223, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Searcy, Arkansas • Huntington Beach, California • San Diego, California + 15 more
- Conditions
- Substance Use Disorders
- Interventions
- IntACT, Usual Care
- Behavioral
- Lead sponsor
- Michael Incze
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Obesity
- Interventions
- Ribupatide, Placebo
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 35
- States / cities
- Mesa, Arizona • Sun City West, Arizona • Irvine, California + 31 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Ogden, Utah
- Conditions
- Eating Disorder Symptom, Fear
- Interventions
- Food Exposure
- Behavioral
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Borderline Personality Disorder, Borderline Personality Pathology, Depressive Symptoms, Emotion Dysregulation, Suicidal Ideation
- Interventions
- Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy
- Drug · Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Saint Louis Park, Minnesota
- Conditions
- Parkinson's Disease
- Interventions
- Levodopa (L-dopa)
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Adult ALL
- Interventions
- V-TARGET intervention
- Device
- Lead sponsor
- The University of Texas at Arlington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Arlington, Texas
- Conditions
- Asthma, Healthy Subjects or Volunteers
- Interventions
- Tralokinumab 300 mg
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Lincoln, Nebraska